Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection

Permanent URI for this collectionhttps://hdl.handle.net/11147/7148

Browse

Filters

2017 - 201912020 - 20221

Settings

Institution Author: search.filters.institutionAuthor.Sezgin, EfeScopus Q: search.filters.scopusQuartile.N/A

Search Results

Now showing 1 - 2 of 2
  • Article
    Citation - WoS: 34
    Citation - Scopus: 32
    Lymphedema After Sentinel Lymph Node Biopsy: Who Is at Risk
    (Mary Ann Liebert, Inc., 2022) Isik, A.; Soran, A.; Grasi, A.; Barry, N.; Sezgin, E.
    Background: Sentinel lymph node biopsy (SLNB) is the accepted approach to stage the clinically negative axilla. The incidence of lymphedema (LE) after SLNB is about 5%. We hypothesize that patients undergoing axillary excision of >5 lymph nodes (LNs) are at increased risk of developing LE. Methods and Results: A single institution prospective breast cancer database was retrospectively reviewed from January 2013 to December 2017, to identify patients who underwent SLNB and were diagnosed with LE. Inclusion criteria was (1) de novo breast cancer, (2) SLNB in clinically node negative patients, and (3) no preoperative diagnosis LE of an extremity. Exclusion criteria was history of axillary lymph node dissection. Age, body mass index, tumor-node-metastasis status, surgery type, neoadjuvant or adjuvant chemotherapy, radiotherapy, and hormone therapy were analyzed. Of the 3325 patients identified, 2940 patients met the inclusion criteria and were included in the final analysis. Median follow-up time was 24 months. Forty-seven (2%) patients were diagnosed with LE, and nine patients (19%) had >5 LNs excised. LE was diagnosed in 3.7% of patients who had >5 LNs excised versus 1.4% of patients with ≤5 LNs excised. Incidence of LE was higher in patients with >5 LNs excision (p = 0.006). Conclusion: Our study showed that patients have a higher likelihood of developing LE when >5 LNs are excised. © Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.
  • Article
    Citation - WoS: 2
    Citation - Scopus: 2
    Evaluation of Hemocytometer Parameters as Potential Biomarkers in Benign Multinodular Goiter and Papillary Thyroid Carcinoma
    (Kowsar Publishing Company, 2017) Uysal, Erdal; Ceylan, Seyit Mehmet; Sezgin, Efe; Bakir, Hasan; Gurer, Ahmet Orhan; Aksoy, Basar; Bastemir, Mehmet
    Background: Hemocytometer parameters can be important biomarkers for some types of cancers and diseases. There is a need to evaluate their biomarker potential in thyroid diseases. Objectives: The current study aimed at contributing to potential biomarker researches to diagnose papillary thyroid carcinoma (PTC) and benign multinodular goiter (BMG), evaluate the role of these markers to determine the PTC characteristics and contribute to clarification of controversial issues. Methods: The study was designed as a retrospective observational study. The study included 389 patients who underwent total thyroidectomy at private Sani Konukoglu hospital (Sanko University, School of Medicine, Gaziantep, Turkey) due to BMG or PTC diagnosis from November 2011 to May 2017. The study subjects were divided into 3 groups. Groups 1, 2, and 3 were subjects with BMG, PTC, and the control, respectively. The comparisons were made among the groups in terms of hemocytometer parameters. In the group with the thyroid papillary carcinoma diagnosis, the relationship between the hemocytometer parameters and the bilateral tumor presence, single-sided multicentrite, and tumor diameter (size) were investigated. Results: Red cell distribution width (RDW) levels were 15.50 +/- 2.39, 15.68 +/- 2.16, and 12.5 +/- 1.51 in the BMG, PTC, and control groups, respectively. Mean platelet volumes (MPV) were 7.97 +/- 1.19, 8.05 +/- 1.20, and 7.23 +/- 1.39 in the BMG, PTC, and control groups, respectively. MPV and RDW values were significantly lower in group 3 compared with the groups 1 and 2 (P < 0.0001). Plateletcrit (PCT) values were 0.22 +/- 0.05, 0.23 +/- 0.06, and 0.19 +/- 0.05 in the BMG, PTC, and control groups, respectively. PCT was significantly lower in the group 3 compared with the groups 1 and 2 (P = 0.0001). In PTC group, no significant relationship was observed between any of the examined hematological parameters in terms of multicentric and bilateral tumor presence. Conclusions: RDW, MPV, haemoglobin content, and PCT were significantly higher in the BMG and PTC groups. This increase was not specific for either of the 2 groups. No significant difference was found between any of the hemocytometer parameters and the multicentricity and bilaterality of PTC. But, a possible correlation was observed between activated partial thromboplastin time (aPTT), hemoglobin content, and tumor size.